ASTH | Ticker Profile - Titan Protect

ASTH

Astrana Health, Inc.

Healthcare · Medical Care Facilities · NCM

$37.99

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.9B

Total market value of the company

Trailing P/E

63.15

Expensive — high growth expected

Forward P/E

11.30

Based on estimated future earnings — lower means cheaper

Rev Growth

+55.6%

Year-over-year revenue change

Profit Margin

0.9%

How much profit the company keeps from each dollar of revenue

ROE

5.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$45.00

+18% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Astrana Health, Inc.

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.

https://www.astranahealth.com

Country: United States Employees: 3,000 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.308

Positive but modest risk-adjusted returns

Kelly Fraction

0.0288

Modest edge detected — smaller position warranted

Calmar Ratio

-0.022

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-1.6%

Historical annualised return based on price data

Max Drawdown

-71.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.99

Less volatile than the market — more defensive

52W High

$39.93

5% below the year high

52W Low

$18.08

110% above the year low

Avg Volume

496,845

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.4%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.61

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

184.46

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.35

Adequate but worth monitoring

Quick Ratio

1.31

Like current ratio but excludes inventory — stricter test

Gross Margin

10.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

3.0%

Profit from core operations before interest and tax

Free Cash Flow

$288M

Positive — the business generates more cash than it spends

Revenue (TTM)

$3.5B

Total revenue over the last 12 months

Net Income

$30M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$50.00

Target Median

$45.00

Target Low

$41.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go